PIWIL2/PDK1 Axis Promotes the Progression of Cervical Epithelial Lesions via Metabolic Reprogramming to Maintain Tumor‐Initiating Cell Stemness
Advanced Science · 2024
DOI: 10.1002/advs.202410756 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Yuebo Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, China-Japan Friendship Hospital, Beijing, 100029, China. Hauptthemen laut MEDLINE: Neoplastic Stem Cells, Uterine Cervical Neoplasms, Pyruvate Dehydrogenase Acetyl-Transferring Kinase, Disease Progression. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National High Level Hospital Clinical Research Funding, National Natural Science Foundation of China.
Abstract (Originalsprache)
When PIWIL2 expression is restored via heterogeneous integration of human papillomavirus, cellular reprogramming is initiated to form tumor‐initiating cells (TICs), which triggers cervical squamous intraepithelial lesions (SIL). TIC stemness is critical for the prognosis of SIL. However, the mechanisms underlying TIC stemness maintenance and tumorigenicity remain unclear. Here, it is revealed that aberrant pyruvate dehydrogenase kinase 1 (PDK1) expression is closely related to aerobic glycolysis in SIL and poor survival in patients with cervical cancer. Mechanistically, that PIWIL2, which induced by stable transfection of either PIWIL2 or HPV16 oncogene E6 in human primary cervical basal epithelial cells and keratinocyte cell line HaCaT, upregulates PDK1 expression via the LIN28/let‐7 axis, hence reprogramming metabolism to activate glycolysis and synchronize with TIC formation. It is further demonstrate that PDK1 is critical for TIC stemness maintenance and tumorigenicity via the PI3K/AKT/mTOR pathway both in vitro and in vivo, revealing a previously unclear mechanism for SIL progression, regression or relapse. Therefore, this findings suggest a potential rationale for prognostic predictions and selecting targeted therapy for cervical lesions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, China-Japan Friendship Hospital, Beijing, 100029, China.
- China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
- VIP Department, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China.
- Department of Obstetrics and Gynecology, The First Affiliated Hospital of University of Science and Technology of China, Hefei, 230001, China.
- Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, 100029, China.
ORCID-Profile: Dingqing Feng
Förderung
- National High Level Hospital Clinical Research Funding
- National Natural Science Foundation of China
Zitieren
APA
Li, Y., Wang, W., Xu, D., Liang, H., Yu, H., Zhou, Y., Liang, J., Sun, H., Liu, X., Xue, M., Ling, B., & Feng, D. (2024). PIWIL2/PDK1 Axis Promotes the Progression of Cervical Epithelial Lesions via Metabolic Reprogramming to Maintain Tumor‐Initiating Cell Stemness. Advanced Science. https://doi.org/10.1002/advs.202410756
Vancouver
Li Y, Wang W, Xu D, Liang H, Yu H, Zhou Y, et al. PIWIL2/PDK1 Axis Promotes the Progression of Cervical Epithelial Lesions via Metabolic Reprogramming to Maintain Tumor‐Initiating Cell Stemness. Advanced Science. 2024. doi:10.1002/advs.202410756
BibTeX
@article{Li2024,
author = {Li, Yuebo and Wang, Wenhui and Xu, Dongkui and Liang, Haiyan and Yu, Huan and Zhou, Ying and Liang, Jing and Sun, Heming and Liu, Xiaodie and Xue, Ming and Ling, Bin and Feng, Dingqing},
title = {PIWIL2/PDK1 Axis Promotes the Progression of Cervical Epithelial Lesions via Metabolic Reprogramming to Maintain Tumor‐Initiating Cell Stemness},
journal = {Advanced Science},
year = {2024},
doi = {10.1002/advs.202410756}
}
EUVIMED